India gives go-ahead for clutch of biosimilar clinical trials
This article was originally published in SRA
Executive Summary
India has permitted more than a dozen clinical trials for r-DNA-based drugs this year including those concerning biosimilar versions of cetuximab (BMS/Lilly's Erbitux), bevacizumab (Roche's Avastin) and rituximab (Roche/Biogen Idec's Rituxan/MabThera) by a clutch of domestic companies1.